Background: Patients with medically unexplained symptoms (MUS) are frequent in primary care and substantially impaired in their quality of life (QoL). Specific training of general practitioners (GPs) alone did not demonstrate sustained improvement at later follow-up in current reviews. We evaluated a collaborative group intervention. Methods: We conducted a cluster randomized controlled trial. Thirty-five GPs recruited 304 MUS patients (intervention group: 170; control group: 134). All GPs were trained in diagnosis and management of MUS (control condition). Eighteen randomly selected intervention GPs participated in training for a specific collaborative group intervention. They conducted 10 weekly group sessions and 2 booster meetings in their practices, together with a psychosomatic specialist. Six and 12 months after baseline, QoL was assessed with the Short-Form 36. The primary outcome was the physical composite score (PCS), and the secondary outcome was the mental composite score (MCS). Results: At 12 months, intention-to-treat analyses showed a significant between-group effect for the MCS (p = 0.023) but not for the PCS (p = 0.674). This effect was preceded by a significant reduction of somatic symptom severity (15-item somatic symptom severity scale of the Patient Health Questionnaire, PHQ-15) at 6 months (p = 0.008) that lacked significance at 12 months (p = 0.078). As additional between-group effects at 12 months, per-protocol analyses showed less health anxiety (Whiteley-7; p = 0.038) and less psychosocial distress (PHQ; p = 0.024); GP visits were significantly (p = 0.042) reduced in the intervention group. Conclusions: Compared to pure GP training, collaborative group intervention achieved a progressive, clinically meaningful improvement in mental but not physical QoL. It could bridge gaps between general practice and mental health care.

1.
Henningsen P, Zipfel S, Herzog W: Management of functional somatic syndromes. Lancet 2007;369:946–955.
2.
Wessely S, White PD: There is only one functional somatic syndrome. Br J Psychiatry 2004;185:95–96.
3.
Henningsen P, Derra C, Turp JC, Häuser W: Functional somatic pain syndromes: summary of hypotheses of their overlap and etiology. Schmerz 2004;18:136–140.
4.
Schröder A, Rehfeld E, Ornbol E, Sharpe M, Licht RW, Fink P: Cognitive-behavioural group treatment for a range of functional somatic syndromes: randomised trial. Br J Psychiatry 2012;200:499–507.
5.
Creed F, Barsky A: A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004;56:391–408.
6.
de Waal MW, Arnold IA, Eekhof JA, van Hemert AM: Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004;184:470–476.
7.
Toft T, Rosendal M, Ornbol E, Olesen F, Frostholm L, Fink P: Training general practitioners in the treatment of functional somatic symptoms: effects on patient health in a cluster-randomised controlled trial (the Functional Illness in Primary Care study). Psychother Psychosom 2010;79:227–237.
8.
Barsky AJ, Orav EJ, Bates DW: Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903–910.
9.
Konnopka A, Schaefert R, Heinrich S, Kaufmann C, Luppa M, Herzog W, König H-H: Economics of medically unexplained symptoms: a systematic review of the literature. Psychother Psychosom 2012;81:265–275.
10.
Aiarzaguena JM, Grandes G, Salazar A, Gaminde I, Sanchez A: The diagnostic challenges presented by patients with medically unexplained symptoms in general practice. Scand J Prim Health Care 2008;26:99–105.
11.
Bullinger M, Kirchberger I: SF-36. Fragebogen zum Gesundheitszustand. Handanweisung und Fragebögen (SF-36 und SF-12). Göttingen, Hogrefe, 1998.
12.
Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV III, Brody D, Davies M: Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 1995;274:1511–1517.
13.
Dickinson WP, Dickinson LM, deGruy FV, Candib LM, Main DS, Libby AM, Rost K: The Somatization in Primary Care Study: a tale of three diagnoses. Gen Hosp Psychiatry 2003;25:1–7.
14.
Kroenke K: Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007;69:881–888.
15.
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 2004;61:1208–1216.
16.
Tschuschke V, Weber R, Horn E, Kiencke P, Tress W: Psychodynamic short-term outpatient group therapy with patients suffering from somatoform disorders. Z Psychiatr Psychol Psychother 2007;55:87–95.
17.
Abbass A, Kisely S, Kroenke K: Short-term psychodynamic psychotherapy for somatic disorders. Systematic review and meta-analysis of clinical trials. Psychother Psychosom 2009;78:265–274.
18.
Rembold SME: Somatoform disorders in primary care settings: construction and evaluation of a psychosocial group programme (in German). Gruppenpsychother Gruppendynamik 2011;47:2–21.
19.
Sattel H, Lahmann C, Gündel H, Guthrie E, Kruse J, Noll-Hussong M, Ohmann C, Ronel J, Sack M, Sauer N, Schneider G, Henningsen P: Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: a randomised controlled trial. Br J Psychiatry 2012;200:60–67.
20.
Stuart S, Noyes R Jr: Interpersonal psychotherapy for somatizing patients. Psychother Psychosom 2006;75:209–219.
21.
Kashner TM, Rost K, Cohen B, Anderson M, Smith GR Jr: Enhancing the health of somatization disorder patients. Effectiveness of short-term group therapy. Psychosomatics 1995;36:462–470.
22.
Potts SG, Lewin R, Fox KA, Johnstone EC: Group psychological treatment for chest pain with normal coronary arteries. QJM 1999;92:81–86.
23.
Tkachuk GA, Graff LA, Martin GL, Bernstein CN: Randomized controlled trial of cognitive-behavioral group therapy for irritable bowel syndrome in a medical setting. J Clin Psychol Med Settings 2003;10:57–69.
24.
Lidbeck J: Group therapy for somatization disorders in general practice: effectiveness of a short cognitive-behavioural treatment model. Acta Psychiatr Scand 1997;96:14–24.
25.
McLeod CC, Budd MA, McClelland DC: Treatment of somatization in primary care. Gen Hosp Psychiatry 1997;19:251–258.
26.
Martin A, Rauh E, Fichter M, Rief W: A one-session treatment for patients suffering from medically unexplained symptoms in primary care: a randomized clinical trial. Psychosomatics 2007;48:294–303.
27.
Fink P, Rosendal M: Recent developments in the understanding and management of functional somatic symptoms in primary care. Curr Opin Psychiatry 2008;21:182–188.
28.
Gask L, Dowrick C, Salmon P, Peters S, Morriss R: Reattribution reconsidered: narrative review and reflections on an educational intervention for medically unexplained symptoms in primary care settings. J Psychosom Res 2011;71:325–334.
29.
Fava GA, Sonino N: Psychosomatic assessment. Psychother Psychosom 2009;78:333–341.
30.
van der Feltz-Cornelis CM, van Oppen P, Ader HJ, van Dyck R: Randomised controlled trial of a collaborative care model with psychiatric consultation for persistent medically unexplained symptoms in general practice. Psychother Psychosom 2006;75:282–289.
31.
Timmer B, Bleichhardt G, Rief W: Importance of psychotherapy motivation in patients with somatization syndrome. Psychother Res 2006;16:348–356.
32.
Reid S, Whooley D, Crayford T, Hotopf M: Medically unexplained symptoms – GPs’ attitudes towards their cause and management. Fam Pract 2001;18:519–523.
33.
Fava GA, Sonino N: Psychosomatic medicine: a name to keep. Psychother Psychosom 2010;79:1–3.
34.
Schröder A, Oernboel E, Licht RW, Sharpe M, Fink P: Outcome measurement in functional somatic syndromes: SF-36 summary scores and some scales were not valid. J Clin Epidemiol 2012;65:30–41.
35.
Kroenke K, Spitzer RL, Williams JB, Lowe B: The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry 2010;32:345–359.
36.
Fink P, Ewald H, Jensen J, Sorensen L, Engberg M, Holm M, Munk-Jorgensen P: Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999;46:261–273.
37.
Christensen KS, Fink P, Toft T, Frostholm L, Ornbol E, Olesen F: A brief case-finding questionnaire for common mental disorders: the CMDQ. Fam Pract 2005;22:448–457.
38.
Conradt M, Cavanagh M, Franklin J, Rief W: Dimensionality of the Whiteley Index: Assessment of hypochondriasis in an Australian sample of primary care patients. J Psychosom Res 2006;60:137–143.
39.
Benedikt G, Schulmeister E, Sattel H, Schaefert R, Sauer N, Herzog W, Henningsen P: Somatic symptoms and illness worries in primary care – a study of 1751 general practice attenders. Z Psychiatr Psychol Psychother 2007;55:21–29.
40.
Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187–193.
41.
Henningsen P, Hartkamp N, Loew T, Sack M, Scheidt CE, Rudolf G: Somatoforme Störungen. Leitlinien und Quellentexte. Stuttgart, Schattauer, 2002.
42.
Schaefert R, Benedikt G, Sauer N, Wilke S, Herzog W, Szecsenyi J, Zipfel S, Henningsen P: FUNKTIONAL project – early recognition and treatment of functional/somatoform complaints in primary care. Notfall Hausarztmedizin 2005;31:580–589.
43.
Schaefert R, Kaufmann C, Bölter R, Faber R, Wild B, Szecsenyi J, Sauer N, Herzog W: Somatoform syndromes in primary care – a manual for interdisciplinary group therapy. Psychotherapeut 2011;56:315–324.
44.
Buffington CA: Developmental influences on medically unexplained symptoms. Psychother Psychosom 2009;78:139–144.
45.
Guthrie E: Adaptation of the psychodynamic-interpersonal model to work with medically unexplained symptoms; in Hardy G, Barkham M, Shapiro D, Guthrie E, Margison F (eds): Psychodynamic-Interpersonal Psychotherapy. Thousand Oaks, Sage, 2012.
46.
Rudolf G: Strukturbezogene Psychotherapie. Leitfaden zur psychodynamischen Therapie struktureller Störungen, ed 2. Stuttgart, Schattauer, 2006.
47.
Fava GA, Sonino N: The biopsychosocial model thirty years later. Psychother Psychosom 2008;77:1–2.
48.
Löwe B, Gräfe K, Zipfel S, Spitzer RL, Herrmann-Lingen C, Witte S, Herzog W: Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians’ diagnosis. J Psychosom Res 2003;55:515–519.
49.
Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737–1744.
50.
United Nations Educational Scientific and Cultural Organization Institute for Statistics: International Standard Classification of Education (ISCED 97). Paris, United Nations Educational Scientific and Cultural Organization, 2006.
51.
Löwe B, Gräfe K, Kroenke K, Zipfel S, Quenter A, Wild B, Fiehn C, Herzog W: Predictors of psychiatric comorbidity in medical outpatients. Psychosom Med 2003;65:764–770.
52.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
53.
Nezu AM, Nezu CM, Lombardo ER: Cognitive-behavioral therapy for medically unexplained symptoms: a critical review of the treatment literature. Behav Ther 2001;32:537–583.
54.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ: Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technol Assess 1999;3:iii–92.
55.
Hanel G, Henningsen P, Herzog W, Sauer N, Schaefert R, Szecsenyi J, Lowe B: Depression, anxiety, and somatoform disorders: vague or distinct categories in primary care? Results from a large cross-sectional study. J Psychosom Res 2009;67:189–197.
56.
Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD: Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003;53:754–760.
57.
Unnebrink K, Windeler J: Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 2001;20:3931–3946.
58.
Hedges LV: Effect sizes in cluster-randomized designs. J Educ Behav Stat 2007;32:341–370.
59.
Wiebe S, Matijevic S, Eliasziw M, Derry PA: Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry 2002;73:116–120.
60.
Smith RC, Lyles JS, Gardiner JC, Sirbu C, Hodges A, Collins C, Dwamena FC, Lein C, William GC, Given B, Goddeeris J: Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med 2006;21:671–677.
61.
Lopez Garcia-Franco A, Cura Gonzalez MI, Caballero ML, Sanz CT, Isabel Diaz GM, Rodriguez Monje MT, Chahua M, Munoz S, I, Serrano GD, Rollan LT, Nieto BE, Losada CL, Caballero MF, Sanz GN, Pose GB, Jurado SM, Luque RM, Garcia de Blas GF, Miguel Abanto MA, Sanz BT, Ayllon CR, Santamaria LI, Santiago Hernando ML, Beltran AR, Aguilar Gutierrez AI, Mota Rodriguez JL, Cosculluela PR, Martin Aragon TL, Bonilla SR, Gonzalez-Granda MC, Rincon RR, de la Ventana MA, Guinea CM, Galindo LH, Barrio Ovalle AB, Martin SM, Fraile PP, Freire HP, Herrera Garcia ML, Lorenzo AA, Garcia IG, Sandino NL, Borja IL, Castro HM, Lumbreras-Villaran P, Ascanio-Duran C: Effectiveness of a cognitive behavioral intervention in patients with medically unexplained symptoms: cluster randomized trial. BMC Fam Pract 2012;13:35.
62.
Kroenke K, Spitzer RL, Williams JB: The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258–266.
63.
Aiarzaguena JM, Grandes G, Gaminde I, Salazar A, Sanchez A, Arino J: A randomized controlled clinical trial of a psychosocial and communication intervention carried out by GPs for patients with medically unexplained symptoms. Psychol Med 2007;37:283–294.
64.
American Psychiatric Association: J 00 Somatic Symptom Disorder. 2012. http://www.dsm5.org/proposedrevision/pages/proposedrevision.aspx?rid=368 (accessed June 20, 2012).
65.
Ellert U, Bellach BM: The SF-36 in the Federal Health Survey – description of a current normal sample (in German). Gesundheitswesen 1999;61(Spec No):S184–S190.
66.
Ware JE Jr: SF-36 Health Survey Manual and Interpretation Guide. Boston, The Health Institute, New England Medical Centre, 1993.
67.
Ware JE Jr: SF-36 health survey update. Spine 2000;25:3130–3139.
68.
Kroenke K: The interface between physical and psychological symptoms. Prim Care Companion J Clin Psychiatry 2003;5(suppl 7):11–18.
69.
olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C: Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J Psychosom Res 2009;66:363–377.
70.
Kleinstäuber M, Witthoft M, Hiller W: Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev 2011;31:146–160.
71.
Creed F: Medically unexplained symptoms – blurring the line between ‘mental’ and ‘physical’ in somatoform disorders. J Psychosom Res 2009;67:185–187.
72.
Dickinson WP, Dickinson LM, deGruy FV, Main DS, Candib LM, Rost K: A randomized clinical trial of a care recommendation letter intervention for somatization in primary care. Ann Fam Med 2003;1:228–235.
73.
Rosendal M, Olesen F, Fink P, Toft T, Sokolowski I, Bro F: A randomized controlled trial of brief training in the assessment and treatment of somatization in primary care: effects on patient outcome. Gen Hosp Psychiatry 2007;29:364–373.
74.
Morriss R, Dowrick C, Salmon P, Peters S, Dunn G, Rogers A, Lewis B, Charles-Jones H, Hogg J, Clifford R, Rigby C, Gask L: Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms. Br J Psychiatry 2007;191:536–542.
75.
Hellman CJ, Budd M, Borysenko J, McClelland DC, Benson H: A study on the effectiveness of two group behavioral medicine interventions for patients with psychosomatic complaints. Behav Med 1990;16:165–173.
76.
Zaby A, Heider J, Schröder A: Waiting, relaxation, or cognitive-behavioral therapy – how effective is outpatient group therapy for somatoform symptoms? Z Klin Psychol Psychother 2008;37:15–23.
77.
Lidbeck J: Group therapy for somatization disorders in primary care: maintenance of treatment goals of short cognitive-behavioural treatment one-and-a-half-year follow-up. Acta Psychiatr Scand 2003;107:449–456.
78.
Arnold IA, Speckens AE, van Hemert AM: Medically unexplained physical symptoms: the feasibility of group cognitive-behavioural therapy in primary care. J Psychosom Res 2004;57:517–520.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.